It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The atypical cadherins Fat and Dachsous are key regulators of cell growth and animal development. In contrast to classical cadherins, which form homophilic interactions to segregate cells, Fat and Dachsous cadherins form heterophilic interactions to induce cell polarity within tissues. Here, we determine the co-crystal structure of the human homologs Fat4 and Dachsous1 (Dchs1) to establish the molecular basis for Fat-Dachsous interactions. The binding domains of Fat4 and Dchs1 form an extended interface along extracellular cadherin (EC) domains 1-4 of each protein. Biophysical measurements indicate that Fat4-Dchs1 affinity is among the highest reported for cadherin superfamily members, which is attributed to an extensive network of salt bridges not present in structurally similar protocadherin homodimers. Furthermore, modeling suggests that unusual extracellular phosphorylation modifications directly modulate Fat-Dachsous binding by introducing charged contacts across the interface. Collectively, our analyses reveal how the molecular architecture of Fat4-Dchs1 enables them to form long-range, high-affinity interactions to maintain planar cell polarity.
Fat and Dachsous are large cadherins that regulate planar polarity as a receptor:ligand pair. Here, authors determine the structure of the Fat:Dachsous complex to uncover the molecular determinants of binding and posttranslational modification.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 H. Lee Moffitt Cancer Center & Research Institute, Department of Drug Discovery, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233); University of South Florida, Cancer Biology Ph.D Program, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
2 Tel Aviv University, School of Neurobiology, Biochemistry, and Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
3 University of South Florida, Cancer Biology Ph.D Program, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); H. Lee Moffitt Cancer Center & Research Institute, Department of Tumor Biology, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233); H. Lee Moffitt Cancer Center & Research Institute, Molecular Medicine Program, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233)
4 H. Lee Moffitt Cancer Center & Research Institute, Department of Tumor Biology, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233); H. Lee Moffitt Cancer Center & Research Institute, Molecular Medicine Program, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233)
5 H. Lee Moffitt Cancer Center & Research Institute, Department of Drug Discovery, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233); H. Lee Moffitt Cancer Center & Research Institute, Molecular Medicine Program, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233)